Vivani Medical Announces $8.25M Private Placement Equity Financing
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated ...
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
Asianet Newsable on MSN1d
Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars
Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...
Vivani Medical prices 7.4M shares at $1.12 in private placement financing
Vivani Medical (VANI) has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of ...
Vivani Medical Gives Data for Weight Loss Implant
By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for ...
Hosted on MSN14d
Vivani treats first patient with long-lasting drug implant for weight loss
A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the first patient with its device. The procedure is part of a first-in-human ...
EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value
Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while focusing on its drug implants.
Drug Delivery Business14d
Vivani reports first human GLP-1 implant for weight loss in adults
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
Drug Delivery Business15d
Vivani to spin out neurostim business, focus on GLP-1 implant
The company wants to create two focused companies dedicated to driving current and future value in their respective therapeutic areas. Vivani aims to continue advancing its miniature GLP-1 therapeutic ...
HC Wainwright Lowers Earnings Estimates for Vivani Medical
HC Wainwright reduced their FY2024 earnings estimates for shares of Vivani Medical in a note issued to investors on Thursday, March 13th. HC Wainwright analyst Y. Chen now forecasts that the company ...
Vivani Withers on Data Release
Vivani Medical, Inc. (NASDAQ: VANI) shares dropped in price Wednesday, as the Alameda, Calif.-based clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, ...
Vivani Medical, Inc.: Vivani Medical Announces $8.25M Private Placement Equity Financing
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant ...